Trusted Resources: People & Places
Online groups, photo galleries and blogs
Stuart Siedman
Director Ben's Dream
Sanfilippo Research Foundation
P.O. Box 81268
Wellesley, Massachusetts, United States
Stuart is the Global Head of Patient Advocacy at Chiesi Rare Diseases where he is responsible for patient advocacy strategy and community engagement across the rare disease portfolio. He has more than 20 years of global advocacy experience both in and outside of the biopharma industry. His most recent experiences were as the Global Director of Public Affairs & Patient Advocacy for the rare blood disorders business unit at Sanofi Genzyme and previously as the leader of Global Patient Advocacy at Bioverativ Therapeutics focusing on their pre-commercial rare disease pipeline.
Stuart is also the Co-founder and Director of the Sanfilippo Research Foundation, a non-profit dedicated to research into Sanfilippo Syndrome/MPS III, a rare inherited lysosomal storage disorder, of which his son Benjamin was a sufferer.
Stuart guided academic-based research from basic science to pre-clinical licensing and was instrumental in building a non-profit consortium that provided funding to launch a company bringing this foundation work to multiple phase I/II gene therapy clinical trials. He participates in number of NGO/GOVT/Industry rare disease groups and associations on advisory boards or as a member. Stuart holds a bachelors degree in Cognitive Science from the University of Rochester.
Related Content
-
Significant Neuropsychiatric Symptoms: Three Mucopolysaccharidosis Type IIIB Cases, Two of Whom Were Siblings With a...Mucopolysaccharidosis (MPS) type IIIB pa...
-
Sanfilippo Children’s Foundation – TwitterSanfilippo Childrens foundation is dedic...
-
Team Sanfilippo FoundationTeam Sanfilippo Foundation is a nonprofi...
-
Sleep-Related Hypermotor Epilepsy in a Patient With Mucopolysaccharidosis Type IIIBoth non-epileptic sleep disturbances an...
-
Losing Stanley – My Little Boy Doesn’t Recognise Me AnymoreLittle Stanley Barnes was diagnosed with...
-
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type ...Currently, there is no effective therapy...
-
Schizophreniform Presentation and Abrupt Neurologic Decline in a Patient With Late-Onset Mucopolysaccharidosis Type ...Due to their low frequency and some atyp...